CANADIAN CANCER TRIALS GROUP – GI DISEASE SITE COMMITTEE

PANCREAS
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO
DATE SATURDAY, APRIL 30th, 2016
TIME: 11:00 - 12:00
CHAIRS: DR. ALICE WEI & DR. DANIEL RENOUF

11:00 WELCOME AND INTRODUCTION DR. A. WEI / DR. D. RENOUF

11:05 ACTIVE TRIALS FOR UPDATE/DISCUSSION

PA.6 (ACCORD 24): RANDOMIZED MULTICENTER PHASE III COMPARISON OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS A COMBINATION OF 5-FLUOROURACIL, LEUCOVORIN, IRINOTECAN AND OXALIPLATIN (MFOLFIRINOX) IN PATIENTS WITH RESECTED PANCREATIC ADENOCARCINOMA DR. A. WEI / DR. J. BIAGI

11:15 APPROVED TRIALS IN DEVELOPMENT

PA.7: A RANDOMIZED PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL VS. GEMCITABINE, NAB-PACLITAXEL AND DURVALUMAB OR GEMCITABINE, NAB-PACLITAXEL, DURVALUMAB AND TREMELIMUMAB AS 1ST LINE THERAPY IN METASTATIC PANCREATIC ADENOCARCINOMA DR. D. RENOUF

CONCEPTS IN DEVELOPMENT

11:35 ALLIANCE 021101: NEOADJUVANT FOLFIRINOX AND CHEMORADIATION FOLLOWED BY DEFINITIVE SURGERY AND POSTOPERATIVE GEMCITABINE FOR PATIENTS WITH BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA: AN INTERGROUP SINGLE_ARM PILOT STUDY DR. A. WEI / DR. S. GALLINGER

11:40 SWOG S1505: FOLFIRINOX VERSUS GEMCITABINE/NAB-PACLITAXEL AS NEOADJUVANT THERAPY FOR RESECTABLE PANCREATIC ADENOCARCINOMA: A RANDOMIZED PHASE II STUDY DR. D. RENOUF

11:45 PHASE II TRIAL OF FOLFIRINOX VERSUS GEMCITABINE/NAB-PACLITAXEL IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC BRCA WT PANCREAS CANCER DR. D. RENOUF

11:50 COMPASS/PANGEN SEQUENCING UPDATE DR. D. RENOUF

11:55 INTERGROUP TASK FORCE UPDATE D. RENOUF / DR. A. WEI

12:00 CLOSING REMARKS